Locally Advanced Esophageal Squamous Cell Carcinoma Clinical Trial
— EC-CRT-007Official title:
Efficacy and Safety of Toripalimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma: a Multicenter, Randomized, Phase II Trial (EC-CRT-007)
Although definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable locally advanced esophageal cancer, elderly patients tolerate intravenous concurrent CRT less well with age and comorbidities. Previous trials have demonstrated that CRT with oral S-1 was tolerable and provided significant survival benefits over radiotherapy alone in elderly patients with esophageal squamous cell carcinoma (ESCC). However, as high as 54% of patients with elderly ESCC experienced locoregional or distant recurrence after CRT. Therefore, a more effective regimen for older patients is needed. Immune checkpoint inhibitors targeting PD-1/PD-L1 have shown substantial clinical benefits in advanced esophageal cancer. Recently, the combination of immunotherapy with CRT has emerged as a promising strategy to improve clinical outcomes in locally advanced esophageal cancer. The aim of this study was to evaluate the efficacy and safety of toripalimab (an anti-PD-1 antibody) after concurrent CRT in elderly patients with locally advanced ESCC.
Status | Recruiting |
Enrollment | 140 |
Est. completion date | December 31, 2028 |
Est. primary completion date | December 31, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 70 Years to 85 Years |
Eligibility | Inclusion Criteria: 1. Histologically confirmed squamous cell carcinoma of the esophagus; 2. Locally advanced, and absence of hematogenous metastasis disease according to UICC TNM version 8; 3. Not suitable for surgery (either for medical reasons or patient's choice); 4. Age at diagnosis 70 to 85 years; 5. No prior cancer therapy; 6. Estimated life expectancy >6 months; 7. Eastern Cooperative Oncology Group performance status = 2 8. No history of concomitant or previous malignancy; 9. The function of important organs meets the following requirements: a. white blood cell count (WBC) =4.0×109/L, absolute neutrophil count (ANC) =1.5×109/L; b. platelets =100×109/L; c. hemoglobin =9g/dL; d. serum albumin =2.8g/dL; e. total bilirubin =1.5×ULN, ALT, AST and/or AKP =2.5×ULN; f. serum creatinine =1.5×ULN or creatinine clearance rate >60 mL/min; 10. Ability to understand the study and sign informed consent. Exclusion Criteria: 1. Patients who have been treated previously with anti-tumor therapy (including chemotherapy, radiotherapy, surgery, immunotherapy, etc.); 2. Patients with hematogenous metastasis disease or esophageal fistula at diagnosis; 3. Known or suspected allergy or hypersensitivity to monoclonal antibodies, any ingredients of cadonilimab, and the chemotherapeutic drugs paclitaxel or cisplatin; 4. Patients who have a preexisting or coexisting bleeding disorder; 5. Inability to provide informed consent due to psychological, familial, social and other factors; 6. Presence of CTC grade =2 peripheral neuropathy; 7. A history of malignancies other than esophageal cancer before enrollment, excluding non-melanoma skin cancer, in situ cervical cancer, or cured early prostate cancer 8. A history of diabetes for more than 10 years and poorly controlled blood glucose levels; 9. Patients who cannot tolerate chemoradiotherapy due to severe cardiac, lung, liver or kidney dysfunction, or hematopoietic disease or cachexia. 10. Active autoimmune diseases, a history of autoimmune diseases (including but not limited to these diseases or syndromes, such as colitis, hepatitis, hyperthyroidism), a history of immunodeficiency (including a positive HIV test result), or other acquired or congenital immunodeficiency diseases, a history of organ transplantation or allogeneic bone marrow transplantation; 11. A history of interstitial lung disease or non-infectious pneumonia; 12. A history of active pulmonary tuberculosis infection within 1 year or a history of active pulmonary tuberculosis infection more than 1 year ago but without formal anti-tuberculosis treatment; 13. Presence of active hepatitis B (HBV DNA = 2000 IU/mL or 104 copies/mL), hepatitis C (positive for hepatitis C antibody, and HCV-RNA levels higher than the lower limit of the assay). |
Country | Name | City | State |
---|---|---|---|
China | Mian Xi | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Sun Yat-sen University | Fifth Affiliated Hospital, Sun Yat-Sen University, Nanfang Hospital, Southern Medical University, Wuhan University, Xiangya Hospital of Central South University, Zhujiang Hospital |
China,
Ji Y, Du X, Zhu W, Yang Y, Ma J, Zhang L, Li J, Tao H, Xia J, Yang H, Huang J, Bao Y, Du D, Liu D, Wang X, Li C, Yang X, Zeng M, Liu Z, Zheng W, Pu J, Chen J, Hu W, Li P, Wang J, Xu Y, Zheng X, Chen J, Wang W, Tao G, Cai J, Zhao J, Zhu J, Jiang M, Yan Y, — View Citation
Liu Y, Zheng Z, Li M, Zhang Y, Zhao F, Gong H, Lin H, Huang W, Chen X, Xu Z, Li X, Liu W, Cui Y, Zheng A, Li B. Comparison of concurrent chemoradiotherapy with radiotherapy alone for locally advanced esophageal squamous cell cancer in elderly patients: A — View Citation
Wang X, Han W, Zhang W, Wang X, Ge X, Lin Y, Zhou H, Hu M, Wang W, Liu K, Lu J, Qie S, Zhang J, Deng W, Wang L, Han C, Li M, Zhang K, Li L, Wang Q, Shi H, Yu Z, Zhao Y, Sun X, Shi Y, Pang Q, Zhou Z, Liang J, Chen D, Feng Q, Bi N, Zhang T, Deng L, Wang W, — View Citation
Zhu Y, Wen J, Li Q, Chen B, Zhao L, Liu S, Yang Y, Wang S, Lv Y, Li J, Zhang L, Hu Y, Liu M, Xi M. Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial. La — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Correlation between immune signature and overall survival | The correlation between pretreatment immune signature (PD-L1, CD8, CTLA-4, CD56, and CD68) by mIHC and overall survival. | From date of enrollment to the date of last follow-up, assessed up to 36 months. | |
Other | Correlation between serum cytokines and overall survival and immune-related adverse events | The correlation between dynamic change of serum cytokines (IL-2R, IL-6, IL-13, IL-8, CCL3, CD40, and CD274) during treatment and survival outcomes and immune-related adverse events. | From date of enrollment to the date of last follow-up, assessed up to 36 months. | |
Primary | Progression-free survival | Three-year follow-up from the date of enrollment to the date of disease progression or last follow-up | From date of enrollment until the date of death from any cause or the date of first documented disease progression whichever came first, assessed up to 36 months. | |
Secondary | Overall survival | Three-year follow-up from the enrollment to the date of death from any cause or date of lost follow-up | From date of enrollment until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 36 months. | |
Secondary | Clinical complete response | Tumor response was evaluated 13-16 weeks after the completion of treatment based on CT or PET-CT scans, and endoscopy with biopsies. | 13-16 weeks after the completion of radiotherapy | |
Secondary | Duration of response | From the date of first CR/PR to the date of first PD. | From date of first CR/PR to the date of first PD according to RECIST criteria, assessed up to 36 months. | |
Secondary | Treatment-related adverse events | Incidence of treatment-related adverse events as assessed by CTCAE v4.0. | From date of enrollment to the date of last follow-up, assessed up to 36 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05743504 -
Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT05520619 -
Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)
|
Phase 2 | |
Recruiting |
NCT04602013 -
Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT05522894 -
AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC
|
Phase 2 | |
Active, not recruiting |
NCT03914443 -
A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma
|
Phase 1 | |
Not yet recruiting |
NCT06426797 -
Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT06342167 -
Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT05130684 -
Neo-NTP-CRT for Locally Advanced ESCC
|
Phase 2 | |
Not yet recruiting |
NCT04888403 -
Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT03917966 -
The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC
|
Phase 2 | |
Not yet recruiting |
NCT06356688 -
A Clinical Study on the Efficacy and Safety of Paclitaxel Polymer Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
|
Phase 2 |